Medijski sadržaj
- Tweetovi
- Tweetovi i odgovori
- Medijski sadržaj, trenutna stranica.
-
Guess what? Anti-PDL1 better than chemo in hi PDL1 NSCLC 1st line
#SITC19#SITC2019. Hardly groundbreaking news, will it help bring prices down?pic.twitter.com/qmFVLypE4o
-
Absolutely mindblowing talk by Ron Germain at
#SITC2019 . Advanced imaging changes understanding of tumor-immune interaction. Never thought that PD1 comes up to slow down T cells!pic.twitter.com/pfAIPjrjEz
Prikaži ovu nit -
Heating up cold melanomas with a TLR9 agonist. 22% response rate with pembro in PD1 nonresponders
#AACR18#AACR2018pic.twitter.com/bI6O6glsfS
-
Basically, after
#AACR18#AACR2018, when you see a NSCLC at any stage including pre-op, ask yourself if there is any reason NOT to give immumo. Otherwise, go for it! Small study, OS awaited, but impressive data on neoadj by D Pardollpic.twitter.com/wRfHzQ8K3E
-
10 muts/Mb SHALL BE your TMB threshold. Almost a Pythagorean beauty in this number, maybe TOO beautiful? Some healthy skepticism by D Rimm (with whom I humbly disagree...)
#AACR18#AACR2018pic.twitter.com/38hfP4lTLK
-
Interesting decision tree for NSCLC after
#AACR18#AACR2018 by N Rizvipic.twitter.com/pFMHT95RnL
-
Guess there is only one reason why we dont routinely use TMB instead of PDL1 to identify pts who benefit from immuno: accessibility to routine NGS. Things MUST change after Checkmate227
#AACR18#AACR2018pic.twitter.com/pJgjv6w57o
-
Now this is interesting. Atezo+beva+CT improves PFS even in EGFR/ALK-mutated NSCLC, for which immuno alone does not work
#AACR2018pic.twitter.com/wWOLyl0poy
-
Good to see I and Roy Herbst agree
#AACR2018 Thanks Roypic.twitter.com/EGOZg1AwNT
-
Booooom
#AACR2018 guess we have a new standard in nonsquamous NSCLC with pembro+pemetr+platinumpic.twitter.com/qKA6R2OT1Q
-
A not-so-far future
#AACR2018. SIRI, tell me how to treat my patient with multiple obscure mutations, then get me a pizza. Love you Siripic.twitter.com/i2u5SaGueG
-
Intriguing findings in the TRACERx studies on lung and renal cancers. 1. Frequent HLA LOH in lung allows immune evasion 2. Chromosomal instability mediates metastases, NOT point mutations. Thanks C Swanton
#AACR2018pic.twitter.com/32qkWYar6o
-
George Coukos frustrated by why ovarian cancers respond poorly to PD1 blockade. TILs are neoantigen-specific, PD1 is expressed and active, so why the hell? Endothelium may exclude T cells from the hot area. Bevacizumab+vaccine may sensitize
#AACR2018pic.twitter.com/LXXELlcLy6
-
Yet another confirmation that PD1 blockade dramatically reduces recurrences after radical surgery in stage 3 melanoma, with moderate tox. But would survival change if we gave pembro at relapse, not before relapse? Crossover in keynote 054 will tell
#AACR2018pic.twitter.com/Cx0zz2VYge
-
Time has come for prospective interventional testing of liquid biopsy, says K Pantel
#AACR2018. should we change our treatment based on LQ?pic.twitter.com/WWRoS6hGKy
-
Brilliant talk by L Fong
#TAT2018 on PD1-CTLA4 combo immunotherapy. Maybe 2 is NOT better than 1 in low burden disease because of T cell hyperactivation-induced cell deathpic.twitter.com/IX9UWF0Gza
-
Geographical and diet-mediated differences in anti-PD1 nonresponders' gut microbiota!
#TAT2018 could this lead to geographical differences in IO trials?pic.twitter.com/TsZAsRNbrB
-
New advices from the
#MDICT on the tough topic of conducting combo immune oncology trials at#TAT2018pic.twitter.com/6vHReuXxdx
-
The future of liquid biopsies, with nucleosome mapping and cpg meth. Brilliant talk by M Speicher at
#MAPonco17pic.twitter.com/upDFFgdT70
-
Normale sabato sera a
#Milano ascaniosforza81.Cori da stadio e lancio di bottiglie nel#naviglio.grazie#Polizia e#carabinieri,sto serenopic.twitter.com/8JsCBfomeX
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.